JP2648434B2 - Pharmaceutical composition containing quinoline or quinazoline derivative - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The present invention relates to an anti-inflammatory agent containing quinoline or a quinazoline derivative, particularly a therapeutic agent for arthritis, and a novel quinoline derivative or a salt thereof useful as an anti-inflammatory agent.

[0002]

2. Description of the Related Art Arthritis is an inflammatory disease of the joint, and the main diseases include rheumatoid arthritis and related diseases in which inflammation is recognized in the joint. In particular, rheumatoid arthritis is also referred to as rheumatoid arthritis, and is a chronic polyarthritis whose main lesion is inflammatory changes in the synovium of the lining of the joint capsule. Arthritis, such as rheumatoid arthritis, is progressive and causes joint disorders such as joint deformation and tonicity,
If they get worse without effective treatment, they often lead to severe physical disability. Conventionally, in treating these arthritis, steroids such as cortisone and other corticosteroids, aspirin, nonsteroidal anti-inflammatory drugs such as piroxicam and indomethacin, gold thiomalate and other gold drugs, chloroquine preparations and D-penicillamine as drug therapy Anti-rheumatic agents, anti-gout agents such as colchicine,
Immunosuppressants such as cyclophosphamide, azathioprine, methotrexate and levamisole have been used.

[0003]

However, these drugs have side effects that make serious or long-term use difficult, are ineffective, or have been used for arthritis that has already developed. There were problems such as not being effective. Therefore, in the clinical practice of arthritis, a drug with low toxicity and excellent in prevention and treatment of arthritis is still desired.

[0004]

DISCLOSURE OF THE INVENTION The present inventors have found that a quinoline or quinazoline derivative in which an optionally oxidized sulfur atom, oxygen atom or alkylene group is bonded to the 2-position via a methylene group can be used as an anti-arthritic agent. The present invention has been found to have an action, an anti-inflammatory action, an antipyretic / analgesic action, an anti-IL-1 activity, an antigen-responsive T cell proliferation inhibitory ability and the like, and is useful as an anti-inflammatory agent, and completed the present invention. That is, the present invention provides:

[0005]

Embedded image

[Wherein, Y represents a nitrogen atom or CG (G represents a carboxyl group which may be esterified),
X represents an optionally oxidized sulfur atom, oxygen atom or-
(CH ₂ ) q- (q represents an integer of 1 to 5), and R represents an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group bonded to X by a ring-constituting carbon atom. And A
The ring and the B ring may each have a substituent. k
Represents 0 or 1. An anti-inflammatory agent comprising a compound represented by the formula (I):

[0007]

Embedded image

Wherein Y represents CG (G represents a carboxyl group which may be esterified), X represents a sulfur atom which may be oxidized or-(CH ₂ ) q- (q represents R represents an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group bonded to X by a ring-constituting carbon atom, and A ring and B ring each represent an integer of 1 to 5. Each may have a substituent. k represents 0 or 1. Or a salt thereof represented by the general formula (II):

[0009]

Embedded image

Wherein Q ¹ represents a leaving group, Y represents CG (G represents a carboxyl group which may be esterified), and ring A and ring B each have a substituent. You may. k represents 0 or 1. And a salt thereof and a compound represented by the general formula (III) R-SH (III): wherein R is an optionally substituted hydrocarbon group or a substituted carbon atom which is bonded to a sulfur atom by a ring-constituting carbon atom. A compound represented by the general formula (I-1): or a salt thereof, and optionally an oxidation reaction.

[0011]

Embedded image

Wherein Y represents CG (G represents a carboxyl group which may be esterified), Z represents a sulfur atom which may be oxidized, and R represents a carbon atom which may be substituted. A hydrogen group or an optionally substituted heterocyclic group bonded to Z by a ring-constituting carbon atom, wherein ring A and ring B may each have a substituent; k represents 0 or 1. And a method for producing a compound represented by the general formula (IV):

[0013]

Embedded image

Wherein Y represents CG (G represents a carboxyl group which may be esterified), Q ² represents a halogen atom, and ring A and ring B each have a substituent. May be. k represents 0 or 1. And a compound represented by the general formula (V) R- (CH ₂ ) _q-1 -CHO (V) wherein R is-(CH) by an optionally substituted hydrocarbon group or a ring-constituting carbon atom. ₂ ) An _optionally substituted heterocyclic group bonded to _q-1- , and q represents an integer of 1 to 5. A compound represented by the general formula (I-2):

[0015]

Embedded image

Wherein Y represents CG (G represents a carboxyl group which may be esterified), and R represents a hydrocarbon group which may be substituted or a ring-constituting carbon atom.
It represents an optionally substituted heterocyclic group bonded to (CH ₂ ) q-, wherein ring A and ring B may each have a substituent. q represents an integer of 1 to 5, and k represents 0 or 1. ] Or a salt thereof.

Formulas (I), (I '), (I-1) and (I-
In 2), (III) and (V), examples of the hydrocarbon group represented by R include an aliphatic chain hydrocarbon group, an alicyclic hydrocarbon group, and an aromatic hydrocarbon group. As the aliphatic chain hydrocarbon group, a linear or branched aliphatic hydrocarbon group, for example, an alkyl group, preferably an alkyl group having 1 to 10 carbon atoms, an alkenyl group, preferably Examples thereof include an alkenyl group having 2 to 10 carbon atoms and an alkynyl group having 2 to 10 carbon atoms. Preferred examples of the alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and se.
c-butyl, tert-butyl, pentyl, isopentyl,
Neopentyl, tert-pentyl, 1-ethylpropyl,
Hexyl, isohexyl, 1,1-dimethylbutyl, 2,
2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, hexyl, pentyl, octyl, nonyl,
Decyl and the like. Preferred examples of the alkenyl group include vinyl, allyl, isopropenyl, 1-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-
Butenyl, 3-butenyl, 2-ethyl-1-butenyl,
3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl,
3-hexenyl, 4-hexenyl, 5-hexenyl and the like. Preferred examples of the alkynyl group include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl,
-Pentynyl, 3-pentynyl, 4-pentynyl, 1-
Hexinyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl and the like can be mentioned.

The alicyclic hydrocarbon group includes a saturated or unsaturated alicyclic hydrocarbon group, for example, a cycloalkyl group, a cycloalkenyl group, a cycloalkadienyl group and the like. Preferred examples of the cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo [2.
2.1] Heptyl, bicyclo [2.2.2] octyl, bicyclo [3.2.1] octyl, bicyclo [3.2.2] nonyl, bicyclo [3.3.1] nonyl, bicyclo [4. 2.1] Nonyl,
Bicyclo [4.3.1] decyl and the like. Preferred examples of the cycloalkenyl group include 2-cyclopentene-
Examples thereof include 1-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1-yl, 3-cyclohexen-1-yl and the like. Preferred examples of the cycloalkadienyl group include 2,4-cyclopentadien-1-yl, 2,4
-Cyclohexadien-1-yl, 2,5-cyclohexadien-1-yl and the like.

The aromatic hydrocarbon group includes a monocyclic or condensed polycyclic aromatic hydrocarbon group, and preferred examples thereof include those having 6 to 6 carbon atoms such as phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl and the like. And 14 aryl groups, among which phenyl, 1-naphthyl, 2-naphthyl and the like are preferable. Formulas (I), (I '), and (I-
In 1), (I-2), (III) and (V), the heterocyclic group represented by R is oxygen, as an atom (ring atom) constituting a ring system,
It means an aromatic heterocyclic group having at least one heteroatom among sulfur and nitrogen, or a saturated or unsaturated non-aromatic heterocyclic group (aliphatic heterocyclic group).

The aromatic heterocyclic group includes an aromatic monocyclic heterocyclic group, an aromatic condensed heterocyclic group and the like. Preferred examples of the aromatic monocyclic heterocyclic group include furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl,
Isothiazolyl, imidazolyl, pyrazolyl, 1,2,3
-Oxadiazolyl, 1,2,4-oxadiazolyl,
1,3,4-oxadiazolyl, furanil, 1,2,3-
Thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4
-Thiadiazolyl, 1,2,3-triazolyl, 1,2,4
-Triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like. Preferred examples of the fused aromatic heterocyclic group include benzofuranyl, isobenzofuranyl, benzo [b] thienyl, indolyl, isoindolyl, 1H-indazolyl, benzimidazolyl, benzooxazolyl, 1,2
-Benzisoxazolyl, benzothiazolyl, 1,2
-Benzoisothiazolyl, 1H-benzotriazolyl,
Quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, naphthyridinyl,
Purinyl, pteridinyl, carbazolyl, α-carbolinyl, β-carbolinyl, γ-carbolinyl, acridinyl, phenoxazinyl, phenothiazinyl, phenazinyl, phenoxathiinyl, thianthrenyl, phenathridinyl, phenatrolinyl, indolizinyl, pyrrolo
[1,2-b] pyridazinyl, pyrazolo [1,5-a] pyridyl, imidazo [1,2-a] pyridyl, imidazo [1,5-a]
Pyridyl, imidazo [1,2-b] pyridazinyl, imidazo
[1,2-a] pyrimidinyl, 1,2,4-triazolo [4,3
-A] pyridyl, 1,2,4-triazolo [4,3-b] pyridazinyl and the like.

Preferred examples of the non-aromatic heterocyclic group include oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuryl, thiolanyl,
Piperidyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, piperazinyl and the like. The above-mentioned aliphatic chain hydrocarbon group, alicyclic hydrocarbon group, aryl group, heterocyclic group and the like may each have one or more, preferably 1 to 3 suitable substituents. Examples of the substituent include a lower alkyl group having 1 to 6 carbon atoms, a lower alkenyl group having 2 to 6 carbon atoms, a lower alkynyl group having 2 to 6 carbon atoms, a cycloalkyl group, an aryl group, and an aromatic heterocyclic group. , A non-aromatic heterocyclic group, an aralkyl group, an amino group, N
A monosubstituted amino group, an N, N-disubstituted amino group, an amidino group, an acyl group, a carbamoyl group, an N-monosubstituted carbamoyl group, an N, N-disubstituted carbamoyl group, a sulfamoyl group, an N-monosubstituted sulfamoyl group, N, N-disubstituted sulfamoyl group, carboxyl group, lower alkoxycarbonyl group having 1 to 6 carbon atoms of alkoxy group, hydroxyl group, lower alkoxy group having 1 to 6 carbon atoms, 2 carbon atoms
Lower alkenyloxy group, cycloalkyloxy group, aralkyloxy group, aryloxy group, mercapto group, lower alkylthio group having 1 to 6 carbon atoms, aralkylthio group, arylthio group, sulfo group, cyano group, azide group, Examples include a nitro group, a nitroso group, and a halogen.

Formulas (I), (I '), (I-1) and (I-
2), (II) and (IV), when Y is a quinoline derivative represented by CG, the esterified carboxyl group represented by G is an alkyloxycarbonyl group;
An aralkyloxycarbonyl group; Examples of the alkyl group in the alkyloxycarbonyl group include an alkyl group having 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like. The aralkyl group in the aralkyloxycarbonyl group means an alkyl group having an aryl group as a substituent (arylalkyl group). Examples of the aryl group include phenyl,
Naphthyl and the like may be mentioned, and these may have the same substituent as the aryl group in the above R has.
The alkyl group is preferably a lower alkyl group having 1 to 6 carbon atoms. Preferred examples of the aralkyl group include, for example, benzyl, phenethyl, 3-phenylpropyl, (1-
Naphthyl) methyl, (2-naphthyl) methyl and the like, among which benzyl, phenethyl and the like are preferable. X
And the optionally oxidized sulfur atom represented by Z include a thio group, a sulfinyl group and a sulfonyl group.

In the general formula (II), the leaving group represented by Q ¹ is, for example, halogen, preferably chlorine, bromine or iodine or a hydroxyl group activated by esterification, for example, an organic sulfonic acid. Residue (e.g., p-toluenesulfonyloxy group, methanesulfonyloxy group, etc.)
And a diphenylphosphoryloxy group, a dibenzylphosphoryloxy group, a dimethylphosphoryloxy group, and the like, which are residues of organic phosphoric acid. In the general formula (IV), examples of the halogen atom represented by Q ² include chlorine, bromine and iodine.

Formulas (I), (I '), (I-1) and (I-
In 2), (II) and (IV), ring A and ring B may have a substituent. Examples of such a substituent include a halogen atom, a nitro group and an optionally substituted alkyl. Group, optionally substituted hydroxyl group, optionally substituted thiol group, optionally substituted amino group, optionally substituted acyl, optionally esterified carboxyl group or substituted And an aromatic ring group which may be used.

Examples of halogen as such a substituent include fluorine, chlorine, bromine and iodine, and fluorine and chlorine are particularly preferred. The alkyl group which may be substituted is a linear, branched or cyclic alkyl group having 1 to 10 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl. Tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, cyclopropyl, cyclobutyl,
Cyclopentyl, cyclohexyl, cycloheptyl and the like can be mentioned.

Examples of the optionally substituted hydroxyl group include a hydroxyl group and an appropriate substituent on the hydroxyl group, particularly a group having a group used as a protecting group for the hydroxyl group, for example, alkoxy, alkenyloxy, aralkyloxy, In addition to acyloxy and the like, aryloxy can be mentioned. Examples of the alkoxy include alkoxy having 1 to 10 carbons (eg, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy,
sec-butoxy, tert-butoxy, pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, nonyloxy, cyclobutoxy, cyclopentoxy, cyclohexyloxy, etc.). Examples of the alkenyloxy include those having 1 to 10 carbon atoms such as allyloxy, crotyloxy, 2-pentenyloxy, 3-hexenyloxy, 2-cyclopentenylmethoxy, and 2-cyclohexenylmethoxy. For example, phenyl-C _1-4 alkyloxy (eg, benzyloxy, phenethyloxy and the like) can be mentioned. As the acyloxy, alkanoyloxy having 2 to 4 carbon atoms (eg, acetyloxy, propionyloxy, n-butyryloxy, iso-butyryloxy, etc.) is preferable. Examples of the aryloxy include phenoxy, 4-chlorophenoxy and the like.

The thiol group which may be substituted includes a thiol group and an appropriate substituent for the thiol group.
In particular, having a group used as a protecting group for a thiol group,
For example, alkylthio, aralkylthio, acylthio and the like can be mentioned. The alkylthio has 1 to 1 carbon atoms.
10 alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, heptylthio, nonylthio, cyclobutylthio, cyclopentylthio , Cyclohexylthio, etc.) are preferred. Examples of the aralkylthio include phenyl -C _1-4 alkylthio (e.g., benzylthio, etc. phenethylthio) and the like. As the acylthio, alkanoylthio having 2 to 4 carbon atoms (eg, acetylthio, propionylthio, n-butyrylthio, iso-butyrylthio, etc.) is preferable.

Examples of the optionally substituted amino group include:
An alkyl group having 1 to 10 carbon atoms, an alkenyl group having 1 to 10 carbon atoms or one or two aromatic groups, an amino group (—NH ₂ group)
Substituted (e.g., methylamino, dimethylamino,
Ethylamino, diethylamino, dibutylamino, diallylamino, cyclohexylamino, phenylamino,
N-methyl-N-phenylamino and the like).

Examples of the optionally substituted acyl include formyl, alkyl having 1 to 10 carbons, and alkyl having 1 to 1 carbons.
0 wherein an alkenyl or aromatic group is bonded to a carbonyl group (e.g., acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, cyclobutanoyl, cyclopentanoyl, cyclohexanoyl, cyclohexanoyl) Heptanoyl, crotonyl, 2-cyclohexenecarbonyl, benzoyl, nicotinoyl and the like).
As the carboxyl group which may be esterified,
Examples include a carboxyl group, an alkyloxycarbonyl group, and an aralkyloxycarbonyl group. Examples of the alkyl group in the alkyloxycarbonyl group include an alkyl group having 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like. The aralkyl group in the aralkyloxycarbonyl group means an alkyl group (arylalkyl group) having an aryl group as a substituent. Examples of the aryl group include phenyl,
And naphthyl and the like, which may have the same substituent as the aryl group in the ring R has. As the alkyl group, a lower alkyl group having 1 to 6 carbon atoms is preferable. Preferred examples of the aralkyl group include:
For example, benzyl, phenethyl, 3-phenylpropyl, (1-naphthylmethyl) methyl, (2-naphthyl)
Methyl and the like, among which benzyl, phenethyl and the like are preferable.

Examples of the optionally substituted aromatic ring group include C _6-14 aromatic hydrocarbon residues such as phenyl, naphthyl and anthryl, and aromatic heterocyclic rings such as pyridyl, furyl, thienyl, imidazolyl and thiazolyl. Residues.

The substituents on ring A and ring B may be substituted at any position on each ring, and may be substituted with 1 to 4 identical or different rings.
When substituents on ring A or ring B are adjacent to each other, linked substituents adjacent, - (CH ₂₎ m-or -
_{O- (CH 2) n-O-} ( here, m is 3-5 integer, n represents 1
Which represents an integer of 3 to 3), and such a ring includes a 5- to 7-membered ring formed together with a carbon atom of a benzene ring.

Among the compounds represented by the general formula (I), the compounds represented by the general formula (I ') are novel. Preferred examples of the compound represented by the general formula (I ′) include the following compounds (Example numbers in parentheses indicate those disclosed in the following Examples). 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(1-methylimidazol-2-yl) sulfinylmethyl] quinoline-3-carboxylic acid ethyl ester (Example 2), 6,7 -Dimethoxy-4- (4-
Methylphenyl) -2-[(1-methyl-imidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 33), 6,7-dimethoxy-4
-(3,4-Dimethoxyphenyl) -2-[(4-methyl-1,2,4-triazol-3-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 3
5),

6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(1-methylimidazole-2
-Yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 36), 6,7-dimethoxy-4-
(3,4-methylenedioxyphenyl) -2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-
3-carboxylic acid ethyl ester (Example 69), 6,7
-Diethoxy-4- (3,4-dimethoxyphenyl)-
2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 72), 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2- [2 -(1-methylimidazole-2
-Yl) ethyl] quinoline-3-carboxylic acid ethyl ester (Example 87)

2-[(2-benzimidazolyl) sulfinylmethyl] -6,7-dimethoxy-4- (3,4-dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester (Example 3), 6,7-dimethoxy -4- (3,4
-Dimethoxyphenyl) -2-[(5-fluorobenzimidazol-2-yl) thiomethyl] quinoline-3-
Carboxylic acid ethyl ester (Example 54), 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-
[(Benzothiazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 60), 6,
7-dimethoxy-4- (3,4-dimethoxyphenyl)
-2-[(3,4-dihydro-4-oxoquinazoline-2
-Yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 64)

6,7-dimethoxy-4- (4-methoxyphenyl) -2-[(benzimidazol-2-yl)
Thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 27), 6,7-dimethoxy-4- (4-methoxyphenyl) -2-[(1-methylimidazole-2)
-Yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 28), 6,7-dimethoxy-4-
(3,4-dimethoxyphenyl) -2-[(4-chlorophenyl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 42), 6,7-dimethoxy-4-
(3,4-dimethoxyphenyl) -2-[(pyrido [1,2
-A] [1,3,4] triazol-5-yl) thiomethyl]
Quinoline-3-carboxylic acid ethyl ester (Example 6
6),

6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(4-chlorophenyl) methylthiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 41), 6,7-dimethoxy -4- (3,4-dimethoxyphenyl) -2-[(benzimidazole-2
-Yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 53), 6,7-dimethoxy-4-
(3,4-dimethoxyphenyl) -2-[[6 (1H)-
Pyrimidone-2-yl] thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 45), 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(3
-Hydroxypyridin-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (Example 46) or 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(2-thiazoline-2 -Yl) thiomethyl]
Quinoline-3-carboxylic acid ethyl ester (Example 4
7). Most preferred examples of the compound (I ′) include 6,7
-Dimethoxy-4- (3,4-dimethoxyphenyl) -2
-[2- (1-methylimidazol-2-yl) ethyl] quinoline-3-carboxylic acid ethyl ester.

The salt of the desired compound (I) of the present invention is preferably a pharmacologically acceptable salt, for example, a salt with an inorganic base, a salt with an organic base, a salt with an inorganic acid, a salt with an organic acid. And salts with basic or acidic amino acids. Preferred examples of the salt with an inorganic base include an alkali metal salt such as a sodium salt and a potassium salt, an alkaline earth metal salt such as a calcium salt and a magnesium salt, and an aluminum salt and an ammonium salt. Preferred examples of the salt with an organic base include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N, N'-dibenzylethylenediamine, and the like. Preferred examples of salts with inorganic acids include:
Salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like can be mentioned. Preferred examples of salts with organic acids include formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p- Salts with toluenesulfonic acid and the like can be mentioned. Preferable examples of the salt with a basic amino acid include salts with arginine, lysine, ornithine and the like, and preferable examples of the salt with an acidic amino acid include salts with aspartic acid, glutamic acid and the like.

The above compound (I) can be produced, for example, as follows. That is, method A

[0039]

Embedded image

Wherein Y ′ is a nitrogen atom or CG ′ (G ′
Represents an esterified carboxyl group), and other symbols are as defined above. In this method, (II) and (II
(I) in a suitable solvent in the presence of a base to give (I-
3) is manufactured. Examples of the solvent include benzene,
Toluene, aromatic hydrocarbons such as xylene, dioxane, tetrahydrofuran, ethers such as dimethoxyethane, alcohols such as methanol, ethanol, propanol, ethyl acetate, acetonitrile, pyridine, N, N-dimethylformamide, dimethylsulfoxide, chloroform, Examples include dichloromethane, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane, acetone, 2-butanone, and a mixed solvent thereof. Examples of the base include alkali metal salts such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, silver carbonate (Ag ₂ CO ₃ ), pyridine, triethylamine, N, N-dimethylaniline and the like. Amines and the like. The amount of the base to be used is preferably about 1 to 5 mol with respect to compound (II). This reaction is carried out usually at -20 ° C to 150 ° C, preferably at about -10 ° C to
Perform at 100 ° C. The quinoline or quinazoline derivative (I-3) thus obtained can be obtained by a known separation and purification means such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer,
It can be isolated and purified by chromatography and the like. Method B In this method , compound (I-4) is produced by subjecting compound (I-4) in which X ′ is a sulfur atom among compounds (I-3) obtained in Method A to an oxidation reaction.

[0041]

Embedded image

Wherein p represents 1 or 2, and the other symbols have the same meanings as described above. This oxidation reaction is carried out according to a conventional method using an oxidizing agent such as m-chloroperbenzoic acid, hydrogen peroxide, a perester, sodium metaperiodate and the like. The oxidizing agent is equimolar to compound (I-4),
Alternatively, when the compound is used in an equimolar amount or less, a compound in which p is 1 in formula (I-5) is preferentially formed. The compound of formula (I-5) where p is 2 is formed by further oxidizing the compound of formula (I-5) where p is 1 when the oxidizing agent is used in an excess of equimolar amount. This oxidation is carried out under an organic solvent which is inert under the reaction conditions, such as halogenated hydrocarbons (e.g.,
The reaction is advantageously performed with methylene chloride, chloroform, dichloroethane and the like, or an aromatic hydrocarbon (eg, benzene, toluene and the like), and alcohols (methanol, ethanol, propanol and the like). This reaction is carried out at room temperature or below, preferably at a temperature of about -50C to 20C, usually for 0.5 to 10 hours. Quinoline derivative thus obtained
(I-5) can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. C method

[0043]

Embedded image

Wherein each symbol has the same meaning as described above. ]
In this method, the phosphonium salt (IV) is condensed with the aldehyde derivative (V) to give (VI), and (VI) is subjected to a reduction reaction to give (I-2)
To manufacture. The condensation reaction between (IV) and (V) is carried out in an appropriate solvent in the presence of a base. As the solvent, methanol,
Alcohols such as ethanol and propanol; ethers such as ethyl ether, dioxane, tetrahydrofuran and dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; dichloromethane;
-Dichloroethane, N, N-dimethylformamide, dimethylsulfoxide and mixed solvents thereof. As the base, sodium hydride, alkali metal hydrides such as potassium hydride, alkoxides such as sodium ethoxide, sodium methoxide, potassium ethoxide, potassium tert. Butoxide, methyl lithium, butyl lithium, phenyl lithium and the like Organic lithium compound sodium amide and the like are used. The amount of the base to be used is preferably about 1-1.5 mol with respect to compound (IV). This reaction is carried out usually at -50 ° C to 100 ° C, preferably at -20 ° C to 50 ° C. Reaction time is 0.5-2
0 hours. (VI) relates to the newly created double bond
It is obtained as a mixture of isomers (E) and (Z). These (E) and (Z) isomers may be subjected to a reduction reaction after isolation or individually without isolation. (I-
2) is manufactured. This reduction reaction in a solvent according to a conventional method, in the presence of a catalyst such as a palladium catalyst (palladium carbon, palladium black, etc.), a platinum catalyst (platinum dioxide, etc.), Raney nickel, etc.
This is performed in a hydrogen atmosphere. As the solvent, methanol, ethanol, alcohols such as propanol, ethyl ether, dioxane, tetrahydrofuran, ethers such as dimethoxyethane, benzene, toluene,
Aromatic hydrocarbons such as xylene, dichloromethane,
Examples thereof include 1,2-dichloroethane, ethyl acetate, acetonitrile, acetone, 2-butanone, N, N-dimethylformamide, dimethyl sulfoxide, and a mixed solvent thereof. The hydrogen atmosphere pressure is 1 to 150 atm, preferably 1 to 20 atm. The quinoline or quinazoline derivative (I-2) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. it can. The starting compounds (II) and (IV) of the present invention can be produced, for example, by the following method. D method

[0045]

Embedded image

Wherein each symbol is as defined above. ]
In this method, 2-aminobenzophenone derivatives (VII) and (VI
(II) in a suitable solvent in the presence of an acid to give (II-
1) is manufactured. Examples of the solvent include benzene,
Aromatic hydrocarbons such as toluene and xylene, ethers such as dioxane, tetrahydrofuran and dimethoxyethane, N, N-dimethylformamide, dimethyl sulfoxide, chloroform, dichloromethane, 1,2-dichloroethane, 1,1,2,2-tetra Chloroethane, acetic acid and the like can be mentioned. The acid includes aluminum chloride,
Examples include Lewis acids such as zinc chloride, p-toluenesulfonic acid, sulfuric acid, and trifluoroacetic acid. The amount of these acids to be used is preferably about 0.05 to 0.5 mol with respect to compound (VII). This reaction is carried out usually at 20 ° C to 200 ° C, preferably at about 30 ° C to 150 ° C. The reaction time is 0.5 to 20 hours, preferably 1 to 10 hours. The compound (II-1) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. Method E

[0047]

Embedded image

Wherein each symbol has the same meaning as described above. ]
In this method, first, a 2-aminobenzophenone derivative (VII)
Is reacted with an acetoacetic ester derivative (IX) in the presence of an acid to give (X), which is then brominated to produce a 2-bromomethylquinoline derivative (II-2). (VII) and (IX)
Can be carried out in the same manner as in Method D. Bromination of (X) can be carried out in a suitable solvent in the presence of a radical reaction initiator according to a conventional method. Examples of the solvent include carbon tetrachloride, chloroform, dichloromethane, 1,
Halogenated hydrocarbons such as 2-dichloroethane, 1,1,2,2-tetrachloroethane and the like can be mentioned. Examples of the radical reaction initiator include benzoyl peroxide, 2,2′-azobis (isobutyronitrile) and the like. The amount of the radical reaction initiator used is 0.00 relative to the compound (X).
About 1 to 0.01 mol is preferable. This reaction is usually performed at 20 ° C.
C. to 150.degree. C., preferably about 30.degree. The reaction time is 0.5 to 20 hours, preferably 1 to 10 hours. The compound (II-2) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. F method

[0049]

Embedded image

Wherein each symbol is as defined above. ]
In this method, a 2-aminobenzophenone derivative (VII) is reacted with a halogenoacetonitrile derivative (XI) to produce a 2-halogenomethylquinazoline derivative (II-3). (VI
The reaction between (I) and (XI) is carried out using an excess of (XI) as a solvent in the presence of an acid. As the acid, those mentioned in Method D are used. The amount of these acids to be used is 1 to 5 with respect to compound (VII).
It is about 1 mol, preferably 1-2 mol. This reaction is generally carried out for 0.5 to 30 hours, preferably 1 to 10 hours. The reaction temperature is usually 20 ° C to 200 ° C, preferably 30 ° C to 1 ° C.
50 ° C. The quinazoline derivative (II-3) thus obtained can be isolated and purified by a known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. G method

[0051]

Embedded image

Wherein each symbol is as defined above. ]
In this method, the 2-aminobenzophenone derivative (VII) is reacted with acetonitrile to form a 2-methylquinazoline derivative.
(XII) was produced, and then (XII) was subjected to a bromination reaction to give 2-
A bromomethylquinazoline derivative (II-4) is produced. (V
The reaction between II) and acetonitrile is performed in the same manner as in Method F.
Bromination of (XII) is carried out in the same manner as bromination of (X) in Method E. The quinazoline derivative (II
-4) is a known separation and purification means, for example, concentration, concentration under reduced pressure,
It can be isolated and purified by solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. H method

[0053]

Embedded image

Wherein each symbol has the same meaning as described above. In this method, compounds (II-1), (II-2), (II-3) and (II-) produced by Method D, Method E, Method F and Method G, respectively.
4) is oxidized to produce compound (II-5). This oxidation reaction is carried out according to a conventional method using an oxidizing agent, for example, m-chloroperbenzoic acid, hydrogen peroxide, a perester, sodium metaperiodate and the like. The oxidizing agent is the compound (II-
1) to (II-2), (II-3) or (II-4)
5 moles, preferably 1 to 3 moles are used. This oxidation is an organic solvent that is inert under the reaction conditions, such as halogenated hydrocarbons (e.g., methylene chloride, chloroform,
The reaction is advantageously carried out in dichloroethane, etc.), aromatic hydrocarbons (eg, benzene, toluene, etc.) and alcohols (methanol, ethanol, propanol, etc.). The reaction temperature is -10C to 150C, preferably about 0C to 100C.
And usually for 0.5 to 10 hours. The quinoline 1-oxide derivative or quinazoline 1-oxide derivative (II-5) thus obtained can be obtained by a known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography. Can be isolated and purified. I method

[0055]

Embedded image

In this method, a compound represented by the general formula (II-6) is reacted with a corresponding amount of triphenylphosphine,
A phosphonium salt derivative represented by the general formula (IV) is produced. This reaction is performed in a solvent, and examples of the solvent include aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as tetrahydrofuran, dioxane, and dimethoxyethane; acetonitrile; and a mixed solvent thereof. This reaction is carried out at 10 ° C to 200 ° C, preferably at 30 ° C.
The reaction is performed at ~ 150 ° C for 0.5 to 50 hours. J method

[0057]

Embedded image

Wherein each symbol has the same meaning as described above. ]
In this method, compound (I-6) is subjected to hydrolysis to produce compound (I-7). The hydrolysis is performed in water or a water-containing solvent according to a conventional method. Examples of the aqueous solvent include water and alcohol (eg, methanol or ethanol), ether (eg, tetrahydrofuran or dioxane), N,
Mixtures with N-dimethylformamide, dimethylsulfoxide, acetonitrile or acetone can be used.
This reaction is carried out in the presence of a base such as, for example, potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide or lithium hydroxide, or an acid such as, for example, hydrochloric acid, sulfuric acid, acetic acid or hydrobromic acid. Preferably, the acid or the base is added in an excess amount to the compound (I-6) (base:
1.2 to 6 equivalents, acid: 2 to 50 equivalents). This reaction is carried out usually at -20 ° C to 150 ° C, preferably at -10 ° C to 1 ° C.
Perform at 00 ° C.

The compound (I) or a salt thereof provided by the present invention has an anti-inflammatory effect, an antipyretic analgesic effect, and is excellent in an experimental model of adjuvant arthritis which develops arthritis similar to human rheumatoid arthritis. Anti-arthritic effect was confirmed. In addition, anti-IL-1 action and antigen-responsive T cell proliferation inhibitory effect were recognized as suggestive mechanisms of the anti-arthritic action of the target compound of the present invention. Further, the toxicity of the compound of the present invention is low.
Compounds synthesized in 6, 45, 47, 54 and 64
No fatal cases were observed when the mice were orally administered at a dose of 00 mg / kg. Therefore, the compounds of the present invention are useful as anti-inflammatory agents for humans and other mammals, particularly as therapeutic agents for arthritis exhibiting inflammatory symptoms.

The compound (I) of the present invention is compounded with a pharmacologically acceptable carrier and is orally administered as a solid preparation such as tablets, capsules, granules and powders, or a liquid preparation such as syrups and injections. Or it can be administered parenterally.
As the pharmacologically acceptable carrier, various organic or inorganic carrier materials commonly used as a drug substance are used, and excipients, lubricants, binders, disintegrants in solid formulations, solvents in liquid formulations, dissolution aids Agents, suspending agents, isotonic agents, buffers, soothing agents and the like. If necessary, formulation additives such as preservatives, antioxidants, coloring agents and sweeteners can also be used.

Preferred examples of the excipient include lactose, sucrose,
D-mannitol, starch, crystalline cellulose, light silicic anhydride, and the like. Preferable examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like. Preferred examples of the binder include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, and the like. Preferred examples of the disintegrant include starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, sodium carboxymethyl starch and the like.

Preferable examples of the solvent in the liquid preparation include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil and the like. Preferable examples of the dissolution aid include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like. Preferred examples of the suspending agent include stearyl triethanolamine,
Surfactants such as sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate,
For example, polyvinyl alcohol, polyvinyl pyrrolidone,
Examples include hydrophilic polymers such as sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose.

Preferable examples of the tonicity agent include sodium chloride, glycerin, D-mannitol and the like. Preferred examples of the buffer include buffers such as phosphate, acetate, carbonate, and citrate. Preferred examples of the soothing agent include benzyl alcohol and the like. Preferable examples of the preservative include p-hydroxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like. Preferable examples of the antioxidant include sulfite, ascorbic acid and the like.

The dose of the compound (I) of the present invention can be variously selected depending on the administration route, the condition of the patient to be treated, and the like.
Normally, for adults, daily oral administration is 5-1000m
g, In the case of parenteral administration, it can be selected from the range of 1 to 100 mg, and these can be administered in 1 to 4 times a day.

Next, test methods for confirming the pharmacological action of the compound (I) of the present invention or a salt thereof and the results thereof will be described. Test Example 1 Effect on Rat-Adjuvant Arthritis Complete Freund's adjuvant (Freun) was injected into the skin of the right hind footpad of male Lewis rats (7-week old, Charles River Japan).
It was sensitized by injecting 0.05 ml of d's complete adjuvant (0.5% suspension of killed M. tuberculosis in liquid paraffin). Test drug
(50mg / kg) in 5% gum arabic and immediately before sensitization
It was administered once a day for 14 days from (Day 0). Immediately before sensitization (D
The left hind limb volume and body weight were measured on days ay 0) and 14 (Day 14), and the rate of inhibition of footpad swelling (%) and the rate of weight gain (%) were determined for the rats to which no drug was administered. The result is Dun
Comparison and test were performed using the nett's test, and a significance level of less than 5% was defined as significant. As shown in Table 1, the compounds of the present invention were effective in suppressing foot pad edema and improving all symptoms of weight gain.

[0066]

[Table 1] Compound Suppression inhibition rate Body weight gain rate (Example number) (%) (%) 2 73 ** 39 ** 33 67 ** 12 36 48 ** 30 ** 69 63 ** 17 72 50 ** 27 ** 35 64 ** 1187 75 ** 27 ** 88 62 ** 24 ****; p <0.01, *; p <0.05

Test Example 2 Inhibitory Effect of Rat Carrageenin Paw Edema Jcl: The volume of the right hind footpad of a male SD rat (6 weeks old) was measured, and the test drug (50 m2) suspended in 5% gum arabic solution was measured.
g / kg) was orally administered. Then, water was additionally administered so that the total administration volume became 5 ml / rat, and one hour later, 0.05 ml of a 1% carrageenin-containing physiological saline suspension was injected subcutaneously into the footpad to induce edema [Winter, Sea・ Aye (Winter,
CA) et al: Proc. Soc. Exp. Biol. Med., 111 , 54.
4 (1962)]. Three hours after carrageenin injection, the volume of the right hind limb was measured again, and the edema inhibition rate was calculated from the difference from the volume before injection. The results are shown in Table 2, and the compound of the present invention showed a carrageenan edema inhibitory effect.

[0068]

[Table 2]

Test Example 3 Analgesic Activity in Mice Slc: ICR male mice (4 weeks old) were orally administered with a drug (50 mg / kg) suspended in a 5% gum arabic solution, and dissolved in 5% ethanol 30 minutes later. 0.1 ml / 10 g body weight of a 0.02% phenylquinone solution was injected intraperitoneally. Thereafter, the writhing and stretching reactions for 20 minutes were calculated for each mouse to determine the analgesic effect of the test drug. [Siegmund, E. et al .; Proc. Soc. Exp. B
iol. Med., 95 , 729 (1957)]. The results are as shown in Table 3, and the compound of the present invention was obtained from mouse phenylquinone.
It showed a significant analgesic effect in the writhing model.

[0070]

[Table 3]  

Test Example 4 Anti-IL-1 Action A known method [Fujio Suzuki et al .: Shinsei Chemistry Laboratory Course, 18, p.
871-875 (1990)], and prepare Dulbecco's medium containing 10% fetal calf serum (Dulbec medium).
co's Medium). Eight days later, various concentrations of the test drug and 0.2 ng / ml of IL-1β were added, and the cells were further cultured for three days, and the amount of extracellular matrix produced was measured. The results were as shown in Table 4. Although IL-1β inhibits the synthesis of extracellular matrix of chondrocytes, the addition of a drug suppresses IL-1 action and restores the amount of extracellular matrix synthesis.

[0072]

[Table 4]

Test Example 5 Antigen-Responsive T Cell Proliferation Inhibition Adjuvant arthritis was induced in male Lewis rats (7 weeks old) according to the method of Test Example 1, and 14 days later, inguinal lymph nodes were removed. Then RPMI-16 containing 5% fetal calf serum
After making a single cell suspension using 40 cultures, the mixture was incubated at 37 ° C. for 1 hour in a nylon wool column.
The cells were eluted from the column with the same culture solution, and the non-adsorbed cell fraction was used as T cells. On the other hand, non-sensitized male Lewis
The T cells were collected from rats (8-9 weeks old) and spleen cells (1 × 10 ⁵ cells / well) irradiated with 20,000 R of soft X-rays
(5 × 10 ⁵ cells / well), PPD (Purified Protein)
Derivatives; final concentration 2 μg / ml) and 2% syngeneic rat serum (treated at 56 ° C. for 30 minutes) at 37 ° C., 5%
The cells were cultured for 72 hours in a carbon dioxide incubator. Furthermore, after adding ³ H-Tdr (0.5 μCi / well) and culturing for 24 hours, the cells were collected and the radioactivity of the incorporated ³ H-Tdr was measured. The test drug was added to the cell suspension immediately before the addition of PPD, and the effect on the incorporation of ³ H-Tdr into cells was examined. The results are shown in Table 5. The compounds of the present invention
It has an inhibitory effect on PD stimulation of T cell proliferation.

[0074]

[Table 5] Compound antigen-responsive T cell proliferation inhibition rate (%) (Example number) 1 μM 10 μM 36 33 79 45 36 70 46 39 92 47 61 61 93 53 51 91 60 59 91 64 53 78

[0075]

EXAMPLES Next, the present invention will be described in more detail by reference examples and examples, but the present invention is not limited to these examples. Reference Example 1 Concentrated sulfuric acid was added to a mixture of 2-amino-3 ', 4'-dimethoxy-4,5-ethylenedioxybenzophenone (6.5 g), ethyl 4-chloroacetoacetate (3.7 g) and acetic acid (60 ml).
(0.3 ml) and stirred at 100 ° C. for 3 hours. The reaction mixture was concentrated under reduced pressure, and the residue was poured into water to give 2N Na.
It was made alkaline with OH and extracted with chloroform. The chloroform layer was washed with water, dried (MgSO ₄ ), and the solvent was distilled off under reduced pressure. The residue was subjected to silica gel column chromatography. From the portion eluted with chloroform-ethyl acetate (7: 3, v / v), 2-chloromethyl-4- (3,4-dimethoxyphenyl) -6,7-ethylenedioxyquinoline-3-
The carboxylic acid ethyl ester (5.5 g, 60%) was obtained. This was recrystallized from acetone. Colorless prism crystals. 197-198 ° C. Elemental analysis Calculated for C ₂₃ H ₂₂ NO ₆ Cl: C, 62.24; H, 5.00;
N, 3.16. Analytical values: C, 61.95; H, 5.15;
N, 3.01.

Reference Examples 2 to 25 In the same manner as in Reference Example 1, the compounds shown in Tables 6 to 8 were obtained.

[0077]

[Table 6]

Note 1) NMR (δ ppm) in CDCl ₃ : 0.92
(3H, t, J = 7.2 Hz), 4.06 (2H, q, J = 7.2
Hz), 5.03 (2H, s), 7.33-7.37 (2H,
m), 7.50-7.55 (3H, m), 7.90-7.98
(2H, m), 8.26 (1H, d, J = 9.4 Hz).

[0079]

[Table 7]

[0080]

[Table 8]

Reference Example 26 Concentrated sulfuric acid was added to a mixture of 2-amino-4,5,3 ', 4'-tetramethoxybenzophenone, ethyl acetoacetate and acetic acid. Dimethoxy-4- (3,4-dimethoxyphenyl) -2-methylquinoline-3-carboxylic acid ethyl ester (83%) was obtained.
This was recrystallized from ethanol. Colorless prism crystals. 147-148 ° C.

REFERENCE EXAMPLE 27 Concentrated sulfuric acid was added to a mixture of 2-amino-4,5,3 ', 4'-tetramethoxybenzophenone, propyl acetoacetate and acetic acid. Dimethoxy-4- (3,4-dimethoxyphenyl) -2-methylquinoline-3-carboxylic acid propyl ester (79%) was obtained. This was recrystallized from ethyl acetate-isopropyl ether. Colorless prism crystals. 153-155 ° C.

Reference Example 28 Concentrated sulfuric acid was added to a mixture of 2-amino-4,5,3 ', 4'-tetramethoxybenzophenone, butyl acetoacetate and acetic acid. Dimethoxy-4- (3,4-dimethoxyphenyl) -2-methylquinoline-3-carboxylic acid butyl ester (53%) was obtained.
This was recrystallized from ethyl acetate-hexane. Colorless prism crystals. 119-120 ° C.

Reference Example 29 6,7-dimethoxy-4- (3,4-dimethoxyphenyl)
-2-methylquinoline-3-carboxylic acid ethyl ester
(411 mg), N-bromosuccinimide (NBS) (214 m
g) A mixture of 2,2'-azobis (isobutyronitrile) (10 mg) and carbon tetrachloride (10 ml) was stirred under reflux for 5 hours. After the reaction mixture was washed with water and dried (MgSO ₄ ), the solvent was distilled off under reduced pressure, and the residue was subjected to silica gel column chromatography. Chloroform-ethyl acetate (10: 1, v
/ V) to give 2-bromomethyl-6,7-dimethoxy-4- (3,4-dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester (285 mg, 58%). This was recrystallized from ethyl acetate-hexane. Colorless prism crystals. 135-136 ° C. Calculated for elemental analysis _{C 23 H 24 NO 6 Br:} C, 56.34; H, 4.93;
N, 2.86. Analytical values: C, 55.98; H, 5.23;
N, 2.62.

Reference Example 30 In the same manner as in Reference Example 29, 2-bromomethyl-6,7-dimethoxy-4- (3,4-dimethoxyphenyl) quinoline-3-carboxylic acid propyl ester (48%) was obtained. This was recrystallized from ethyl acetate-isopropyl ether. Colorless prism crystals. 144-145 ° C. Calculated for elemental analysis _{C 24 H 26 NO 6 Br:} C, 57.15; H, 5.20;
N, 2.78. Analytical values: C, 56.75; H, 5.30;
N, 2.68.

Reference Example 31 In the same manner as in Reference Example 29, butyl 2-bromomethyl-6,7-dimethoxy-4- (3,4-dimethoxyphenyl) quinoline-3-carboxylate (56%) was obtained. This was recrystallized from ethyl acetate-ether. Colorless prism crystals. 160-161 ° C. Calculated for elemental analysis _{C 25 H 28 NO 6 Br:} C, 57.92; H, 5.44;
N, 2.70. Analytical values: C, 57.96; H, 5.53;
N, 2.50.

Reference Example 32 2-chloromethyl-6,7-dimethoxy-4- (3,4-
Dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester (3.0 g), metachloroperbenzoic acid (85%, 2.
A mixture of 3 g) and methanol (40 ml) was stirred under reflux for 2 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and the residue was poured into chloroform. The chloroform layer is washed with water,
After drying (MgSO ₄ ), the solvent was distilled off under reduced pressure, and the residue was subjected to silica gel column chromatography. From the portion eluted with chloroform-ethyl acetate (6: 4, v / v), 2-chloromethyl-6,7-dimethoxy-4- (3,4-dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester 1-oxide (2.0 g, 65%). This was recrystallized from acetone-isopropyl ether. Colorless prism crystals. Melting point 193-194 [deg.] C. Elemental analysis Calculated for C ₂₃ H ₂₄ NO ₇ Cl: C, 59.81; H, 5.24;
N, 3.03. Analytical values: C, 59.69; H, 5.32;
N, 3.05.

Reference Example 33 Powdered aluminum chloride (6.7 g) was added to a mixture of 2-amino-4,5,3 ', 4'-tetramethoxybenzophenone (8.0 g) and chloroacetonitrile (25 ml), and the mixture was heated at 100 ° C.
For 2 hours. The reaction mixture was poured into water and extracted with chloroform. The chloroform layer is washed with water and dried (MgSO 4
₄ ) After that, the solvent was distilled off, and the residue was subjected to silica gel column chromatography. Chloroform-ethyl acetate (10:
1, v / v), 2-chloromethyl-6,
7-Dimethoxy-4- (3,4-dimethoxyphenyl) quinazoline (4.9 g, 52%) was obtained. Recrystallized from acetone. Colorless prism crystals. 183-184 ° C.

Reference Example 34 2-Chloromethyl-6,7-diethoxy-4- (3,4-
A mixture of dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester (7.1 g), triphenylphosphine (3.9 g) and toluene (70 ml) was stirred under reflux for 2 hours. After cooling, the precipitated solid was collected by filtration and [6,7-diethoxy-
4- (3,4-Dimethoxyphenyl) -3-ethoxycarbonylquinolin-2-yl] methyltriphenylphosphonium chloride (9.6 g, 87%) was obtained. Melting point 172
１７174 ° C. (decomposition).

Reference Example 35 In the same manner as in Reference Example 34, [6,7-dimethoxy-4- (3,
4-dimethoxyphenyl) -3-ethoxycarbonylquinolin-2-yl] methyltriphenylphosphonium
Chloride was obtained. 200-202 ° C (decomposition).

Reference Example 36 In the same manner as in Reference Example 34, [6,7-dimethoxy-4- (4
-Methoxyphenyl) -3-ethoxycarbonylquinolin-2-yl] methyltriphenylphosphonium chloride was obtained. Melting point 178-180 [deg.] C (decomposition).

Reference Example 37 In the same manner as in Reference Example 34, [6,7-dimethoxy-4- (3,
4-Dimethoxyphenyl) quinazolin-2-yl] methyltriphenylphosphonium chloride was obtained. Melting point 20
8-210 ° C (decomposition).

Reference Example 38 In the same manner as in Reference Example 1, 2-chloromethyl-4- (3,4
-Dimethoxyphenyl) -6-methylquinoline-3-carboxylic acid ethyl ester was obtained. Recrystallized from ethanol. Colorless prism crystals. 125-126 ° C.

Reference Example 39 Sodium iodide (1.68 g) and methyl ethyl ketone
(15 ml) was stirred at 80 ° C. for 1 hour.
Chloromethyl-6,7-dimethoxy-4- (3,4-dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester (2.0 g) was added, and the mixture was further stirred at the same temperature for 12 hours. The insoluble solid was filtered off, and the filtrate was concentrated under reduced pressure. The residue was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO ₄ ), after which the solvent was distilled off. The remaining oil was subjected to silica gel column chromatography,
From the portion eluted with chloroform-ethyl acetate (1: 1, v / v), 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-iodomethylquinoline-3-carboxylic acid ethyl ester (1. 4 g, 58%). Recrystallized from ethyl acetate-hexane. Colorless prism crystals. 170-171 ° C. Elemental analysis Calculated for C ₂₃ H ₂₄ NO ₆ I: C, 51.41; H, 4.50; N,
2.61. Analytical values: C, 51.25; H, 4.53; N,
2.58.

Example 1 2-chloromethyl-6,7-dimethoxy-4- (3,4-
Dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester (3.0 g), 1-ethyl-2-mercaptoimidazole (1.0 g), potassium carbonate (1.1 g) and N, N-
A mixture of dimethylformamide (30 ml) was stirred at room temperature for 3 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried (MgSO ₄ ), and the solvent was distilled off under reduced pressure. The residue was subjected to silica gel column chromatography, and chloroform-ethyl acetate (3: 2, v / v) was used.
From the part eluted with v), 2-[(1-ethylimidazole-
2-yl) thiomethyl] -6,7-dimethoxy-4- (3,
4-Dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester (2.8 g, 78%) was obtained. This was recrystallized from ethyl acetate-hexane. Colorless prism crystals. 157-158 ° C. Elemental analysis Calculated for C ₂₈ H ₃₁ N ₃ O ₆ S: C, 62.55; H, 5.81;
N, 7.82. Analytical values: C, 62.55; H, 5.84;
N, 7.79.

Example 2 6,7-Dimethoxy-4- (3,4-dimethoxyphenyl)
-2-[(1-Methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (3.0 g)
To a dichloromethane (75 ml) solution was added metachloroperbenzoic acid (85%, 830 mg) in small portions under ice-cooling. The reaction mixture was stirred at room temperature for 2.5 hours and then 5% NaHSO ₃
The extract was washed with an aqueous solution, a saturated aqueous solution of sodium hydrogen carbonate and water in that order, and dried (MgSO ₄ ). After distilling off the solvent under reduced pressure, the residue was subjected to silica gel column chromatography, and from the portion eluted with ethyl acetate-methanol (10: 1, v / v), 6,7-dimethoxy-4- (3,4- Dimethoxyphenyl)
-2-[(1-Methylimidazol-2-yl) sulfinylmethyl] quinoline-3-carboxylic acid ethyl ester
(1.8 g, 58%). This was recrystallized from acetone-ethyl ether. Colorless prism crystals. Melting point 193-194 [deg.] C. Elemental analysis C ₂₇ H ₂₉ N ₃ O ₇ calculated for S: C, 60.10; H, 5.42;
N, 7.79. Analytical values: C, 59.80; H, 5.60;
N, 7.51.

Example 3 In the same manner as in Example 2, 2-[(2-benzimidazolyl) sulfinylmethyl] -6,7-dimethoxy-4-
(3,4-Dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester was obtained. This was recrystallized from acetone. Colorless prism crystals. 160-161 ° C. Calculated for elemental analysis _{C 30 H 29 N 3 O 7} S: C, 62.60; H, 5.08;
N, 7.30. Analytical values: C, 62.21; H, 5.10; N,
7.09.

Example 4 6,7-Dimethoxy-4- (3,4-dimethoxyphenyl)
-2-[(1-Methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (2.5 g)
To a dichloromethane (60 ml) solution under ice-cooling was added metachloroperbenzoic acid (85%, 2.5 g) in small portions. The reaction mixture was stirred at room temperature for 4 hours, and then washed with a 5% aqueous NaHSO ₃ solution, a saturated aqueous sodium hydrogen carbonate solution and water in that order.
Dried (MgSO ₄ ). After evaporating the solvent under reduced pressure, the residue was subjected to silica gel column chromatography, and the residue eluted with ethyl acetate-methanol (10: 1, v / v) from 6.7
-Dimethoxy-4- (3,4-dimethoxyphenyl) -2
-[(1-methylimidazol-2-yl) sulfonylmethyl] quinoline-3-carboxylic acid ethyl ester (1.5
g, 58%). This was recrystallized from acetone-ethyl ether. Colorless prism crystals. 183-184 ° C. Elemental analysis C ₂₇ H ₂₉ N ₃ O ₈ calculated for S: C, 58.37; H, 5.26;
N, 7.56. Analytical values: C, 58.46; H, 5.24;
N, 7.20.

Example 5 In the same manner as in Example 4, 2-[(2-benzimidazolyl) sulfonylmethyl] -6,7-dimethoxy-4- (3,
4-Dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester was obtained. This was recrystallized from acetone-isopropyl ether. Colorless prism crystals. Melting point 181-182 [deg.] C. Elemental analysis Calculated for C ₃₀ H ₂₉ N ₃ O ₈ S: C, 60.90; H, 4.94;
N, 7.10. Analytical values: C, 60.76; H, 4.86;
N, 7.09.

Example 6 6,7-Dimethoxy-4- (3,4-dimethoxyphenyl)
-2-[(1-Methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (4.9 g)
A solution of hydrogen chloride in ethanol (27%, 1.3 g) was added dropwise to an ethanol (100 ml) solution at room temperature. About 2 /
The solvent of No. 3 was distilled off, and ethyl ether was added to the residue, and the precipitated crystals were collected by filtration. The collected crystals were recrystallized from isopropanol to give 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(1-methylimidazole-
2- (yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester hydrochloride monohydrate (3.0 g, 55%) was obtained. Colorless prism crystals. 133-134 ° C. Elemental analysis _{C 27 H 29 N 3 O 6} S · HCl · H 2 calculated for O: C, 56.10;
H, 5.58; N, 7.27. Analytical value: C, 55.84;
H, 5.72; N, 7.16.

Example 7 2-bromomethyl-6,7-dimethoxy-4- (3,4-
A mixture of (dimethoxyphenyl) -quinoline-3-carboxylic acid propyl ester (3.3 g), 2-mercapto-1-methylimidazole (821 mg), potassium carbonate (1.08 g) and N, N-dimethylformamide (60 ml) was prepared. Stir at room temperature for 3 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried (MgSO ₄ ), and the solvent was distilled off under reduced pressure. The residue was subjected to silica gel column chromatography, and chloroform-ethyl acetate was used.
(7: 3, v / v) eluted with 6,7-dimethoxy-
4- (3,4-Dimethoxyphenyl) -2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid propyl ester (1.77 g, 51%) was obtained.
This was recrystallized from acetone-isopropyl ether. Colorless prism crystals. 131-132 ° C. Elemental analysis Calculated for C ₂₈ H ₃₁ N ₃ O ₆ S: C, 62.55; H, 5.81;
N, 7.82. Analytical values: C, 62.18; H, 5.72;
N, 7.73.

Example 8 In the same manner as in Example 7, 6,7-dimethoxy-4- (3,
4-Dimethoxyphenyl) -2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid butyl ester (60%) was obtained. This was recrystallized from ethyl acetate-hexane. Colorless prism crystals. 131-132 ° C. Calculated for elemental analysis _{C 29 H 33 N 3 O 6} S: C, 63.14; H, 6.03;
N, 7.62. Analytical values: C, 62.87; H, 6.00;
N, 7.39.

Example 9 In the same manner as in Example 1, 6,7-dimethoxy-4- (3,
4-Dimethoxyphenyl) -2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid methyl ester (69%) was obtained. This was recrystallized from acetone-ether. Colorless prism crystals. 159-160 ° C. Elemental analysis Calculated for C ₂₆ H ₂₇ N ₃ O ₆ S: C, 61.28; H, 5.34;
N, 8.25. Analytical values: C, 61.05; H, 5.59;
N, 8.13.

Example 10 In the same manner as in Example 1, 6,7-dimethoxy-4- (2-
Methoxyphenyl) -2-[(1-methylimidazole-
2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (89%) was obtained as an oil. NMR (δ ppm) CDCl ₃ in: 0.90 (3H, t, J = 7H
z), 3.34 (3H, s), 3.70 (3H, s), 3.74 (3H,
s), 3.98 (2H, q, J = 7 Hz), 4.03 (3H, s), 4.6
4 (2H, s), 6.66 (1H, s), 6.86 (1H, s), 7.01
−7.16 (4H, m), 7.34 (1H, s), 7.45 (1H, dou
blet, J = 8 and 2Hz).

This oil was dissolved in ethanol (15 ml) and a solution of hydrogen chloride in ethanol (23%, 1.2 g) was added. The solvent was distilled off under reduced pressure to give 6,7-dimethoxy-4-.
(2-Methoxyphenyl) -2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester hydrochloride (2.0 g) was obtained. This was recrystallized from ethanol-ether. Light yellow prism crystal. 180-181 ° C. Elemental analysis _{C 26 H 27 N 3 O 5} S · HCl · 1 / 2H 2 O as Calculated: C, 57.9
3; H, 5.42; N, 7.80. Analytical value: C, 58.0
5; H, 5.32; N, 7.72.

Example 11 In the same manner as in Example 1, 6,7-dimethyl-4- (3,4
-Dimethylphenyl) -2-[(1-methylimidazole
-2-yl) thiomethyl] quinoline-3-carboxylate
The crude ester (97%) was obtained as an oil. NMR (δ ppm) CDCl_ThreeMiddle: 0.93 (3H, t,J= 7H
z), 2.31 (3H, s), 2.32 (3H, s), 2.35 (3H,
s), 2.44 (3H, s), 3.42 (3H, s), 4.03 (2H, q,
J= 7Hz), 4.61 (2H, s), 6.88 (1H, d,J= 1H
z), 7.03-7.10 (3H, m), 7.23 (1H, d,J= 8
Hz), 7.35 (1H, s), 7.78 (1H, s).

The oil was dissolved in ethanol (10 ml) and a solution of hydrogen chloride in ethanol (23%, 0.584 g) was added. The solvent was distilled off under reduced pressure to give 6,7-dimethyl-4.
-(3,4-Dimethylphenyl) -2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester hydrochloride (1.1 g) was obtained. Recrystallized from ethanol-ether. Light yellow prism crystal. 133-134 ° C. Elemental analysis _{C 27 H 29 N 3 O 2} S · HCl · 3 / 2H 2 calculated for O: C, 62.0
0; H, 6.36; N, 8.03. Analytical value: C, 62.3
1; H, 6.01; N, 7.98.

Example 12 In the same manner as in Example 1, 6,7-dimethoxy-4- (3,
4-Dimethoxyphenyl) -2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester 1-oxide (69%) was obtained. This was recrystallized from ethyl acetate-hexane. Colorless prism crystals. Melting point 171-172 [deg.] C. Elemental analysis C ₂₇ H ₂₉ N ₃ O ₇ calculated for S: C, 60.10; H, 5.42;
N, 7.79. Analytical values: C, 60.29; H, 5.53;
N, 7.49.

Examples 13 to 72 In the same manner as in Example 1, the compounds shown in Tables 9 to 17 were obtained.

[0110]

[Table 9]

[0111]

[Table 10]

[0112]

[Table 11]

[0113]

[Table 12]

[0114]

[Table 13]

[0115]

[Table 14]

[0116]

[Table 15]

[0117]

[Table 16]

[0118]

[Table 17]

Examples 73 to 75 The compounds of Table 18 were obtained in the same manner as in Example 1.

[0120]

[Table 18]

Example 76 2-Chloromethyl-6,7-dimethoxy-4- (3,4-
A mixture of dimethoxyphenyl) quinazoline (4.5 g), 2-mercaptoethanol (1.13 g), potassium carbonate (2.8 g) and N, N-dimethylformamide (50 ml) was stirred at room temperature for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate layer is washed with water and dried (MgSO ₄ )
After the solvent was distilled off, 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(2-hydroxyethylthio)
Methyl] quinazoline (4.1 g, 82%) was obtained. Recrystallized from ethanol. Colorless prism crystals. Melting point 154-15
5 ° C.

Examples 77 to 83 The compounds of Table 19 were obtained in the same manner as in Example 76.

[0123]

[Table 19] Examples 84 to 86 The compounds of Table 20 were obtained in the same manner as in Example 2.

[0124]

[Table 20]

Example 87 [6,7-Dimethoxy-4- (3,4-dimethoxyphenyl) -3-ethoxycarbonylquinolin-2-yl] methyltriphenylphosphonium chloride (17.4 g) was added to ethanol of sodium ethoxide. The solution [prepared from Na (0.62 g) and ethanol (150 ml)] was added at room temperature. Then, a solution of 2-formyl-1-methylimidazole (3.7 g) in ethanol (20 ml) was added dropwise. The mixture was stirred at room temperature for 3 hours, poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried (MgSO ₄ ), and the solvent was distilled off. The residue was subjected to silica gel column chromatography. From the portion eluted with chloroform-methanol (100: 1, v / v), (E) -6,7-dimethoxy-4- (3,4
-Dimethoxyphenyl) -2- [2- (1-methylimidazol-2-yl) vinyl] quinoline-3-carboxylic acid ethyl ester (8.3 g, 67%) was obtained. Recrystallized from ethyl acetate. Colorless prism crystals. 206-208 ° C.
Then, from the eluted part, (Z) -6,7-dimethoxy-4
-(3,4-Dimethoxyphenyl) -2- [2- (1-methylimidazol-2-yl) vinyl] quinoline-3-carboxylic acid ethyl ester (2.6 g, 21%) was obtained as an oil. NMR (δ ppm in CDCl ₃ ): 0.96 (3H, t, J =
7Hz), 3.35 (3H, s), 3.78 (3H, s), 3.87 (3
H, s), 3.96 (3H, s), 3.97 (3H, s), 3.98 (2
H, q, J = 7 Hz), 6.69 (1 H, d, J = 12 Hz), 6.8
-7.1 (7H, m), 7.13 (1H, s). (E)-and (Z) -6,7-dimethoxy-4- (3,4-
Dimethoxyphenyl) -2- [2- (1-methylimidazol-2-yl) vinyl] quinoline-3-carboxylic acid ethyl ester was converted to ethanol-tetrahydrofuran, respectively.
(1: 1, v / v) in the presence of 5% palladium on carbon under hydrogen atmosphere at 1 atm for hydrogenation reaction to give 6,7-dimethoxy-
4- (3,4-dimethoxyphenyl) -2- [2- (1-methylimidazol-2-yl) ethyl] -quinoline-3-
The carboxylic acid ethyl ester was obtained. Recrystallized from ethanol. Colorless prism crystals. 147-148 ° C.

Example 88 [6,7-Dimethoxy-4- (3,4-dimethoxyphenyl) quinazolin-2-yl] methyltriphenylphosphonium chloride (9.1 g) was dissolved in a solution of sodium ethoxide in ethanol [Na (0 .394 g) and ethanol (100 ml)] at room temperature. Then, a solution of 2-formyl-1-methylimidazole (1.7 g) in ethanol (10 ml) was added dropwise. The mixture was stirred at room temperature for 3 hours, poured into water and extracted with chloroform. The chloroform layer is washed with water,
After drying (MgSO ₄ ), the solvent was distilled off, and the residue was silica gel
It was subjected to column chromatography. From the part eluted with chloroform-methanol (20: 1, v / v), (E)-
6,7-dimethoxy-4- (3,4-dimethoxyphenyl)
2- [2- (1-Methylimidazol-2-yl) vinyl] quinazoline (5.1 g, 82%) was obtained. Ethanol
Recrystallized from chloroform. Colorless prism crystals. Melting point 2
54-255 ° C. Elemental analysis _{C 24 H 24 N 4 O 4} · 3 / 2H 2 calculated for O: C, 62.73; H, 5.92; N, 12.19 analysis: C, 62.62; H, 5.85 ; N, 11.90

Next, (Z) -6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2- [2
-(1-Methylimidazol-2-yl) vinyl] quinazoline (0.61 g, 10%) was obtained. Recrystallized from ethanol-chloroform. Colorless platelets. Melting point 180-181
° C. Elemental analysis _{C 24 H 24 N 4 O 4} · 1 / 2H 2 calculated for O: C, 65.29; H, 5.71; N, 12.69 analysis: C, 65.28; H, 5.66 ; N, 12.42 (E) - And (Z) -6,7-dimethoxy-4- (3,4-
Each of dimethoxyphenyl) -2- [2- (1-methylimidazol-2-yl) vinyl] quinazoline was dissolved in chloroform-ethyl acetate (1: 1, v / v) in the presence of 5% palladium carbon under a hydrogen atmosphere. Subjected to a hydrogenation reaction at atmospheric pressure
7-dimethoxy-4- (3,4-dimethoxyphenyl)-
2- [2- (1-methylimidazol-2-yl) ethyl]
Quinazoline was obtained. Recrystallized from ethyl acetate. Colorless prism crystals. 170-171 ° C.

Examples 89 to 94 The compounds of Table 21 were obtained in the same manner as in Example 87.

[0129]

[Table 21]

Example 95 6,7-Dimethoxy-4- (3,4-dimethoxyphenyl)
-2- [2- (1-Methylimidazol-2-yl) ethyl] quinoline-3-carboxylic acid ethyl ester (9.0 g)
In ethanol (40 ml) and ethanolic hydrogen chloride
(22%, 10 g) was added. After stirring the mixture at room temperature for 5 minutes, ether (150 ml) was added, and the precipitated crystals were collected by filtration.
Recrystallized from ethanol-ether, 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2- [2- (1-
Methyl imidazol-2-yl) ethyl] quinoline-3-
The carboxylic acid ethyl ester dihydrochloride (9.1 g) was obtained.
Light yellow prism crystal. 158-160 ° C. Elemental analysis _{C 28 H 31 N 3 O 6} · 2HCl · 1 / 3C 2 H 5 OH · 1/2
Calculated value for H ₂ O: C, 57.11; H, 6.02; N, 6.97 Analytical value: C, 57.03; H, 6.15; N, 7.00

Example 96 [6,7-Dimethoxy-4- (3,4-dimethoxyphenyl) -3-ethoxycarbonylquinolin-2-yl] methyltriphenylphosphonium chloride (3.0 g) was added to sodium ethoxide in ethanol. The solution [prepared from Na (0.13 g) and ethanol (45 ml)] was added at room temperature. Then 3
-(1-Methylimidazol-2-yl) propionaldehyde (0.787 g) was added. The mixture was stirred at room temperature for 3 hours, poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried (MgSO ₄ ), and the solvent was distilled off. The residue was subjected to silica gel column chromatography. From the part eluted with ethyl acetate-methanol (30: 1, v / v), (E) -6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2- [2- [2- (1 -Methylimidazol-2-yl) ethyl] vinyl] quinoline-3-carboxylic acid ethyl ester (0.36 g, 15%) was obtained as an oil. NMR (δ ppm in CDCl ₃ ): 1.03 (3H, t, J =
7Hz), 2.7-3.0 (4H, m), 3.60 (3H, s), 3.7
9 (3H, s), 3.87 (3H, s), 3.97 (3H, s), 4.05
(3H, s), 4.09 (2H, q, J = 7 Hz), 6.7-7.2 (8
H, m), 7.43 (1H, s). Then, from the eluted part, (Z) -6,7-dimethoxy-4
-(3,4-dimethoxyphenyl) -2- [2- [2- (1-
Methyl imidazol-2-yl) ethyl] vinyl] quinoline-3-carboxylic acid ethyl ester (0.2 g, 8%) was obtained as an oil. NMR (δ ppm in CDCl ₃ ): 1.02 (3H, t, J =
7Hz), 2.8-3.2 (4H, m), 3.58 (3H, s), 3.8
0 (3H, s), 3.88 (3H, s), 3.96 (3H, s), 4.05
(3H, s), 4.07 (2H, q, J = 7 Hz), 6.08 (1H, d
t, J = 7.4 & 11.4 Hz), 6.6-7.0 (7H, m), 7.
42 (1H, s). (E)-and (Z) -6,7-dimethoxy-4- (3,4-
A mixture of dimethoxyphenyl) -2- [2- [2- (1-methylimidazol-2-yl) ethyl] vinyl] quinoline-3-carboxylic acid ethyl ester in ethanol-tetrahydrofuran (1: 4, v / v) Hydrogenation reaction at 1 atm under a hydrogen atmosphere in the presence of 5% palladium carbon, and treated with ethanolic hydrochloric acid to give 6,7-dimethoxy-4- (3,4
-Dimethoxyphenyl) -2- [4- (1-methylimidazol-2-yl) butyl] quinoline-3-carboxylic acid ethyl ester was obtained. Recrystallized from chloroform-ethyl acetate. Pale yellow crystals. 180-183 ° C. Elemental analysis _{C 30 H 35 N 3 O 6} · 2HCl · H 2 calculated for O: C, 5
7.69; H, 6.29; N, 6.73 Analytical value: C, 57.48; H, 6.09; N, 6.60

Example 97 2-Chloromethyl-6,7-dimethoxy-4- (3,4-
Dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester (1.5 g), 2-hydroxy-6-methylpyridine (0.4 g), potassium carbonate (0.511 g) and N, N-
The mixture of dimethylformamide (20 ml) was
After stirring for an hour, the mixture was poured into water and extracted with ethyl acetate.
The ethyl acetate layer was washed with water and dried (MgSO ₄ ), after which the solvent was distilled off. The residual oil was subjected to silica gel column chromatography, and from the portion eluted with ethyl acetate, 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-
[(2-methyl-6-pyridyl) oxymethyl] quinoline-
3-Carboxylic acid ethyl ester (0.79 g, 46%) was obtained. Recrystallized from chloroform-hexane. Yellow prism crystals. 173-174 ° C. Calculated for elemental analysis _{C 29 H 30 N 2 O 7} : C, 67.17; H, 5.83; N,
5.40 Analytical values: C, 66.97; H, 6.02; N,
5.16

Example 98 2-Iodomethyl-6,7-dimethoxy-4- (3,4-
Dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester (9.0 g), 2-hydroxy-1-methylimidazole (1.8 g), silver (I) carbonate (Ag ₂ CO ₃ ) (5.1 g) and benzene ( (100 ml) was stirred at 50 ° C. for 18 hours and the insoluble solid was filtered off. The filtrate is washed and dried
After (MgSO ₄ ), the solvent was distilled off. The residual oil was subjected to silica gel column chromatography, and chloroform-
From the portion eluted with ethyl acetate (5: 1, v / v), 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-
[(1-Methyl-2-imidazolyl) oxymethyl] quinoline-3-carboxylic acid ethyl ester (0.8 g, 9%) was obtained. Recrystallized from ethyl acetate-hexane. Colorless prism crystals. 151-152 ° C. Calculated for elemental analysis _{C 27 H 29 N 3 O 7} : C, 63.90; H, 5.87; N,
8.28 Analytical values: C, 63.74; H, 5.87; N,
7.99

Example 99 6,7-Dimethoxy-4- (3,4-dimethoxyphenyl)
-2-[(1-Methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester (0.6
g), 2N NaOH (1.7 ml) and ethanol (12 m
The mixture of l) was refluxed for 6 hours. The reaction mixture was concentrated in vacuo. The residue is diluted with water, washed with ethyl acetate and washed with 2
Acidified with N hydrochloric acid and extracted with ethyl acetate. The extract was washed with water, dried (MgSO ₄ ) and concentrated in vacuo to give crystals.
Recrystallized from ethanol-ethyl ether to give 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-
[(1-Methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid (0.3 g, 53%) was obtained as colorless prisms. 213-214 ° C. Elemental analysis _{C 25 H 25 N 3 O 6} S · 1 / 2H 2 calculated for O: C, 59.5
1; H, 5.19; N, 8.32 Analytical value: C, 59.3
8; H, 5.40; N, 7.93

[0135]

According to the present invention, there is provided a novel anti-inflammatory agent containing quinoline or a quinazoline derivative, particularly a therapeutic agent for arthritis, a novel quinoline derivative or a salt thereof used therefor, and a method for producing the derivative.

──────────────────────────────────────────────────続 き Continuation of the front page (51) Int.Cl. ⁶ Identification code Agency reference number FI Technical indication location C07D 239/76 C07D 239/76 Application for accelerated examination

Claims (16)

(57) [Claims] 1. A compound of the general formula (I) [In the formula, Y represents a nitrogen atom or CG (G represents a carboxyl group which may be esterified.), And X represents a sulfur atom which may be oxidized, an oxygen atom or-(CH ₂ ) q- (q
Represents an integer of 1 to 5. ), R is bonded to X by an optionally substituted aliphatic chain hydrocarbon group, alicyclic hydrocarbon group or aromatic hydrocarbon group, or a ring-constituting carbon atom, and oxygen, sulfur, nitrogen Represents an optionally substituted aromatic heterocyclic group having at least one heteroatom or a saturated or unsaturated non-aromatic heterocyclic group, wherein ring A and ring B each have a substituent. You may. k represents 0 or 1. ] Or a salt thereof. 2. The anti-inflammatory agent according to claim 1, wherein X is-(CH ₂ ) q-. 3. The anti-inflammatory agent according to claim 1, wherein Y is CG and G is a C _1-6 alkyloxycarbonyl group. 4. The anti-inflammatory agent according to claim 1, wherein X is a thio group, a sulfinyl group or a sulfonyl group. 5. The anti-inflammatory agent according to claim 4, wherein X is a thio group. 6. The anti-inflammatory agent according to claim 1, wherein q is 1. 7. The anti-inflammatory agent according to claim 3, wherein the C _1-6 alkyloxycarbonyl group represented by G is an ethoxycarbonyl group. 8. A ring and a B ring each independently represent a halogen atom, a nitro group, an optionally substituted alkyl group, an optionally substituted hydroxyl group, an optionally substituted thiol group, The same or different ones selected from the group consisting of an optionally substituted amino group, an optionally substituted acyl group, an optionally esterified carboxyl group and an optionally substituted aromatic ring group
May be substituted by to 4 substituents, further, linked substituents adjacent, - (CH ₂₎ m- or -O- (C
H ₂₎ n-O- (here, m is 3-5 integer, anti-inflammatory agents n is 1 to 3 indicates an integer) rings formed have may claim 1 represented by. 9. The anti-inflammatory agent according to claim 8, wherein the substituent on the ring A is methoxy located at the 6-position and the 7-position of the quinoline ring. 10. The anti-inflammatory agent according to claim 8, wherein the substituent on ring B is methoxy or methylenedioxy. 11. The anti-inflammatory agent according to claim 10, wherein the methoxy group is located at the 3- and 4-position of the B ring. 12. The anti-inflammatory agent according to claim 1, wherein k is 0. 13. The compound according to claim 1, wherein the compound is ethyl 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(1-methylimidazol-2-yl) sulfinylmethyl] quinoline-3-carboxylate. 6,7-dimethoxy-4- (4-methylphenyl) -2
-[(1-methyl-imidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester, 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(4-methyl-1 , 2,4-triazole-
3-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester, 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-3 -Carboxylic acid ethyl ester, 6,7-dimethoxy-4- (3,4-methylenedioxyphenyl) -2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester, 6 , 7-Diethoxy-4- (3,4-dimethoxyphenyl) -2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester, 6,7-dimethoxy-4- (3 , 4-Dimethoxyphenyl) -2- [2- (1-methylimidazol-2-yl) ethyl] quinoline-3-carboxylic acid ethyl ester, 2-[(2-benzo Imidazolyl) sulfinyl methyl]
-6,7-dimethoxy-4- (3,4-dimethoxyphenyl) quinoline-3-carboxylic acid ethyl ester, 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(5-fluoro Benzimidazole-2-
Ethyl) thiomethyl] quinoline-3-carboxylic acid ethyl ester, ethyl 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(benzothiazol-2-yl) thiomethyl] quinoline-3-carboxylate Ester, ethyl 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(3,4-dihydro-4-oxoquinazolin-2-yl) thiomethyl] quinoline-3-carboxylate, 6 , 7-Dimethoxy-4- (4-methoxyphenyl)-
2-[(benzimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester, 6,7-dimethoxy-4- (4-methoxyphenyl)-
2-[(1-methylimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester, 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(4-chlorophenyl) thiomethyl ] Quinoline-3-carboxylic acid ethyl ester, 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(pyrido [1,2-a] [1,3,4] triazole-5- Yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester, 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(4-chlorophenyl) methylthiomethyl]
Quinoline-3-carboxylic acid ethyl ester, 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[(benzimidazol-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester, 6, 7-dimethoxy-4- (3,4-dimethoxyphenyl) -2-[[6 (1H) -pyrimidone-2-yl] thiomethyl] quinoline-3-carboxylic acid ethyl ester, 6,7-dimethoxy-4- ( 3,4-dimethoxyphenyl) -2-[(3-hydroxypyridin-2-yl) thiomethyl] quinoline-3-carboxylic acid ethyl ester or 6,7-dimethoxy-4- (3,4-dimethoxyphenyl) -2 -[(2-thiazolin-2-yl) thiomethyl]
The anti-inflammatory agent according to claim 1, which is quinoline-3-carboxylic acid ethyl ester. 14. The anti-inflammatory agent according to claim 1, which is a joint destruction inhibitor. 15. The anti-inflammatory agent according to claim 1, which is an anti-rheumatic agent. 16. The method according to claim 1, which is an anti-rheumatic rheumatoid arthritis agent.
The anti-inflammatory agent as described above.